A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
Recruiting in Palo Alto (17 mi)
+82 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Pfizer
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.
Research Team
PC
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Eligibility Criteria
Inclusion Criteria
Subjects must be overweight (BMI 27- 50 kg/m2)
Subjects must have type 2 diabetes mellitus
Treatment Details
Interventions
- CP-945,598 (Other)
- CP-945,598 Treatment B (Other)
- Placebo (Other)
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: CP-945,598 Treatment BExperimental Treatment1 Intervention
Subjects receive CP-945,598 plus non-pharmacological weight loss program.
Group II: CP-945,598Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Pfizer Investigational SiteAlbuquerque, NM
Pfizer Investigational SiteBay City, MI
Pfizer Investigational SiteWashington, United States
Pfizer Investigational SiteOrlando, FL
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Trials
4712
Patients Recruited
50,980,000+
Known For
Vaccine Innovations
Top Products
Viagra, Zoloft, Lipitor, Prevnar 13